1. Market Research
  2. > Biotechnology
  3. > Biological Therapy Market Trends
  4. > Competitor Analysis: CD19-Targeted Therapeutics

Competitor Analysis: CD19-Targeted Therapeutics

  • October 2013
  • -
  • La Merie Publishing
  • -
  • 34 pages

Renewed interest in CD19 as target for antibody and T-cell Therapeutics

The human CD19 antigen is a 95 kd transmembrane glycoprotein. It is specifically expressed in normal and neoplastic B cells, as well as follicular dendritic cells. CD19 serves as a diagnostic marker for B-cell malignancies. Virtually all cases of acute lymphoblastic leukemia (ALL) are CD19 positive. Years ago, naked antibodies have been generated against CD19, but clinical results were not sufficiently satisfactory. With the advent of new technologies to increase effector funtions of antibodies and to engineer cytotoxic T-lymphocytes to redirect them to CD19, this target has regained considerably interest in oncology.


The present Competitive Intelligence report about CD19-Targeted Therapeutics provides a competitor evaluation in the field of antibody- and T-cell-based therapeutics for the treatment of B-cell hematologic malignancies as of October 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.


The report includes a compilation of currently active projects in research and development of antibodies and T-cells targeting CD19 and with enhanced effector fucntion. In addition, the report lists company-specific R&D pipelines of CD19-Targeted Therapeutics. Competitor projects are listed in a tabular format providing information on:


-Drug Codes,
-Target / Mechanism of Action,
-Class of Compound,
-Company,
-Product Category,
-Indication,
-R&D Stage and
-additional comments with a hyperlink leading to the source of information.


About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis: CD19-Targeted Therapeutics
Competitor Analysis: CD19-Targeted Therapeutics

Table of Contents


-Fc-Engineered CD19-Targeted Monoclonal Antibodies
-CD19-Targeted Antibody-Drug Conjugates
-CD19-Targeted Immunotoxin          
-Bispecific, CD19-Targeted and T-Cell Redirecting Monoclonal Antibodies
-Autologous CD19-Targeted T-Cells
-Allogeneic CD19-Targeted T-Cells
-Corporate and Academic CD19-Targeted Therapeutics Pipelines

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Flat-Rate Access to R&D Database & Reports from La Merie Publishing

Flat-Rate Access to R&D Database & Reports from La Merie Publishing

  • $ 8470
  • Industry report
  • November 2016
  • by La Merie Publishing

Flat-Rate Access to R&D Database & Reports from La Merie Publishing - R&D Drug Pipeline Database: 1-Year Subscription - Flat-Rate Subscription to La Merie Publishing Reports & News Services A one-yea ...

Bioprinting: Technologies and Global Markets

Bioprinting: Technologies and Global Markets

  • $ 6650
  • Industry report
  • October 2016
  • by BCC Research

Use this report to: - Understand market dynamics of bioprinting technologies, applications, and end-user industries. - Assess specific bioprinting-related industries, including 3-D cell culture; bioinks; ...

Stem Cell Assay Market by Type, Kit, Product, Application, End User - Forecast to 2021

Stem Cell Assay Market by Type, Kit, Product, Application, End User - Forecast to 2021

  • $ 6328
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global stem cell assay market is expected to reach USD 1,363.3 million by 2021 from USD 536.6 million in 2016, at a CAGR of 20.5% from 2016 to 2021. Factors such as high prevalence of chronic diseases, ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.